Development of screening method for intranasal influenza vaccine and adjuvant safety in preclinical study

• Published in: Biologicals Vol. 55; pp. 43 - 52
• Main Authors: Hiradate, Yuki, Sasaki, Eita, Momose, Haruka, Asanuma, Hideki, Furuhata, Keiko, Takai, Mamiko, Aoshi, Taiki, Yamada, Hiroshi, Ishii, Ken J., Tanemura, Kentaro, Mizukami, Takuo, Hamaguchi, Isao
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.09.2018
• Subjects: Adjuvant; Adjuvants, Immunologic - chemistry; Adjuvants, Immunologic - pharmacology; Administration, Intranasal; Alum; Animals; Biomarkers; clinical trials; cluster analysis; DMXAA; Drug Evaluation, Preclinical; Female; Influenza A Virus, H1N1 Subtype - chemistry; Influenza A Virus, H1N1 Subtype - immunology; influenza vaccines; Influenza Vaccines - chemistry; Influenza Vaccines - immunology; Influenza Vaccines - pharmacology; intranasal administration; lungs; Mice; Mice, Inbred BALB C; NanoSiO2; Pam3CSK4; phenotype; Preclinical study; QuantiGene plex; screening; T-lymphocytes; toxicity; vaccine adjuvants; Vaccine safety; QuantiGene plex; Preclinical study; Vaccine safety; Nlrp3; DMXAA; SA; IFN; RE; WBCs; Biomarkers; Pam3CSK4; HA; STING; Adjuvant; QGP; TLR; Alum; HAv; WPv; NanoSiO2; PamCSK; NanoSiO

Recently, many vaccine adjuvants have been developed; however, most of the newly developed adjuvants have been dropped out of preclinical and clinical trials owing to their unexpected toxicity. Thus, the development of highly quantitative and comparable screening methods for evaluating adjuvant safe...